These findings indicate that further pre-clinical studies to ascertain the suitability of 111In-labeled 067-213 as a probe to noninvasively monitor CD73 status in cancer patients receiving CD73-targeted immune checkpoint therapy are appropriate. The gene discussed is NT5E; the disease is cancer.